<![CDATA[Conclusions and Award Ceremony]]>
Trending
- CELMoD Potency and Cereblon-Mediated Activity in Multiple Myeloma
- <![CDATA[Conclusions and Award Ceremony]]>
- Mixed T-cell chimerism at 3 months predicts late relapse in acute myeloid leukemia after allogeneic stem cell transplantation
- FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
- AI’s Evolving Role in Radiation Oncology
- Alcohol-related cancer deaths in US have more than doubled over three decades | Alcohol
- AI-Driven Auto-Contouring and Planning Enable Precise Radiation Oncology
- Why Do Radiotherapy Access Gaps Persist Even in Wealthy Countries?

![<![CDATA[Conclusions and Award Ceremony]]> Guilherme Perini, MD, PhD, explained the rationale behind the KEYFORM-008 trial, exploring how targeting LAG-3 can reverse checkpoint inhibitor resistance.](https://news.shareyourcancerstories.com/wp-content/uploads/2026/06/ltCDATAReviewing-the-HIMALAYA-Trial-of-Tremelimumab-Plus-Durvalumab-in-Unresectable-768x432.png)